ISPO

Published in Cancer Detection and Prevention 1998; 22(Supplement 1).

Studies on the humoral immune response to hemagglutinin and neuraminidase of influenza vaccine in children with acute lymphoblastic leukemia

LB Brydak Ph D Assoc Prof 1, R Rokicka-Milewska MD Prof 2, M Machala MSc 1, T Jackowska MD 2

1National Influenza Center WHO, Nat. Inst. of Hygiene, Warsaw, Poland 2 Dept. of Pediatrics Hematology Oncology, Medical Academy, Warsaw, Poland

AIM: The aim of this study was to assess the humoral response to hemagglutinin and neuraminidase of influenza vaccine in children with acute lymphoblastic leukemia. METHODS: The study group consisted of 22 patients vaccinated against influenza for the first time in the epidemic season 1993/94 (one dose, Wyeth, USA), then in 1996/97 (one dose, Solvay Duphar, Holland). Hemagglutinin inhibition and neuraminidase inhibition tests were used to measure antibody levels before vaccination, 3 weeks and 6 months after vaccination. RESULTS: Three weeks after immunization in 1993/94 the protection rates amounted to 40.9%-100% and 50%-86.4% six months after vaccination. After 1996/97 protection rates were 50%-90.9% three weeks after vaccination and 63.6%-100% six months after vaccination. After the first vaccination mean fold increases of antineuraminidase antibody levels ranged from 14.8 to 35.1 three weeks after immunization and from 11.9 to 35.8 after six months. In 1996/97 antineuraminidase antibody levels three weeks after vaccination were 9.3-14.3 times higher than values before vaccination and after six months they were 15.3-23.0 times higher. CONCLUSIONS: The results of this study indicate that subunit influenza vaccines were immunogenic in children with acute lymphoblastic leukemia and induced a production of antihemagglutinin and antineuraminidase antibodies in high levels.

KEY WORDS: influenza, hemagglutinin, neuraminidase, neuraminidase, vaccination, vaccine, leukemia, .

Paper presented at the International Symposium on the Impact of Biotechnology on Prediction, Prevention and Treatment of Cancer; Nice, France; October 24 - 27, 1998; in the section on Immunotherapy.

http://www.cancerprev.org/Journal/Issues/22/101/19/2941